Dear Colleagues, As the 2020 pandemic has altered our behavioral, economic, educational policies, and numerous other career and life events worldwide, SARS-CoV-2 has also impacted global healthcare and patient outcomes. Fortunately, and not unexpectedly, frontline and advanced line healthcare workers, researchers, and scientists have never ceased the tradition of tireless sacrifice and dedication to advancing patient care. Assuredly we have reviewed and read exceptional cancer care advancements in 2020, including innovative efforts for delivering care via ambulatory processes or through virtual technologies while prioritizing our most vulnerable patient populations. Fortunately, numerous diagnostic and therapeutic advancements in 2020 have occurred in Genitourinary Oncology.

While safeguarding both patients and the healthcare team from unnecessary risk of SARS-CoV-2, telehealth technology and its widespread adoption among healthcare practitioners and patients have allowed for innovative patient care strategies. Virtual education has also persevered and improved during this year of in-person and travel adversity.
Welcome to the third issue of Everyday Urology - Oncology Insights of 2020, published by Digital Science Press. This issue focuses on advances in the management of non-muscle-invasive bladder cancer and upper tract urothelial carcinoma; it also spotlights GU cancer care advancements from 2020 virtual global meetings.

This issue's cover story is written by Patrick J. Hensley, MD, Urological Oncology Fellow, and world-renowned urologist, Ashish M. Kamat from the University of Texas MD Anderson Cancer Center, Houston, Texas, entitled: “Overcoming Diagnostic and Therapeutic Challenges in Non-muscle Invasive Bladder Cancer (NMIBC)”. In 2020, approximately 81,000 cases of urothelial carcinoma of the bladder will be diagnosed in the United States, with nearly 18,000 associated deaths.¹ In their review article, Drs. Kamat and Hensley discuss current challenges in NMIBC, emerging diagnostic approaches, and advances in both intravesical and systemic therapy.

Sam S. Chang, MD, MBA, provides a concise and well-balanced update on low-grade upper tract urothelial carcinoma in the expert perspective article. Upper tract urothelial carcinomas (UTUCs) are a heterogeneous group of malignancies arising from the urothelium within the renal pelvis or upper ureter.

Dear Colleagues,

Welcome to the second issue of Everyday Urology – Oncology Insights of 2020, published by Digital Science Press. Throughout the year, UroToday.com has provided information and expert perspectives on the evolving state of urology and GU oncology, as well as the impact COVID-19 has had on the healthcare environment, featuring video discussions amongst physicians at the frontlines of care and research. These videos, along with discussions of conference updates, journal clubs and the cancer patient journey series are featured on the UroToday.com website. This issue focuses on advances in the management of prostate cancer, as well as the ASCO 2020 virtual meeting held May 29-31, 2020.

In their article, “What is Changing in Advanced Prostate Cancer?” Christopher J.D. Wallis, MD, Ph.D., and Zachary Klaassen, MD, profile the ways in which advanced prostate cancer treatment has been revolutionized over the last 15 years, as no less than nine novel agents have been introduced with proven overall survival benefits. Reviewing the evidence that has defined these changes, Dr. Wallis and Dr. Klaassen detail the pivotal trials and FDA approvals that have demonstrated survival benefits across metastatic castration-resistant prostate cancer (mCRPC), metastatic castration sensitive prostate cancer (mCSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC), beginning with the introduction of docetaxel for men with castration-resistant prostate cancer in 2004, and continuing through recent phase 3 trials as well as reviewing novel treatment strategies.

Dear Colleagues,

Welcome back to another issue of Everyday Urology - Oncology Insights, the first issue of 2020 brought to you by UroToday. In the featured articles of this issue, we highlight the work of Edward Schaeffer, MD, PhD, and Ashley Baker, MD, presentations as well as work from Noah Hahn, MD, in a presentation I stepped in and gave at the 2019 Large Urology Group Practice Association (LUGPA) Continued Medical Education (CME) Program. This meeting’s agenda collectively focused on Leveraging Disruptive Technology: Pragmatic and Productive Advances for your Practice, which included a variety of presentations in prostate, bladder, and renal cancers as well as bladder health, minimally invasive procedures and preparing your clinics for the evolving future.

At the 2019 LUGPA CME, Dr. Edward Schaeffer presented on the relevancy of traditional culture testing in urinary tract infections (UTIs). Given the varying degree of complication associated with UTIs, Dr. Schaeffer highlights the available options for testing and treatment. He concludes by dissecting the benefits and pitfalls of a few of his most recommended tests and points out that clinical outcomes will ultimately depend on the nuances of symptoms that result from a host’s response to bacteria. 
Welcome to the final 2019 issue of Everyday Urology - Oncology Insights. On December 6, 2019, UroToday celebrated its sixteenth year online. In our continuous effort to provide both concise and clinically relevant updates in urologic oncology, UroToday has established itself as a trusted leader in expounding the importance of multidisciplinary care models, emphasizing perspectives on rapidly changing and relevant topics in urology and GU Oncology, highlighting selected and specific studies,

Dear Colleagues,

Welcome back to Everyday Urology - Oncology Insights. As is our journal’s goal, this issue will illuminate recent advances within the management armamentarium of Urologic Oncology by featuring clinical care updates and expert opinions. In this issue, Everyday Urology focuses on advanced prostate cancer, highlighting recent additions to the nmCRPC treatment landscape as well as the emerging role of theranostics. Finally, our spotlight features coverage of the Advanced Prostate Cancer Consensus Conference, (APCCC 2019) held August 29 - 31, 2019 in Basel, Switzerland.

Welcome to the second issue of the fourth volume of Everyday Urology - Oncology Insights. This issue turns its focus to prostate cancer, with insight from experts Fred Saad, MD, FRCS, and Sanjeev Kaul, MD, MCh. Our spotlight features reports from the American Society of Clinical Oncologists annual meeting, which gathered medical oncologists and healthcare professionals from around the world between May 31 and June 4, 2019 for insightful presentations which provide key data and guide advances in clinical practice.
Welcome to the current issue of Everyday Urology – Oncology Insights. We begin this issue with our cover story: “Optimizing TURBT and Optical Diagnostics in Bladder Cancer,” authored by Ashish Kamat, MD. Dr. Kamat discusses the crucial importance of performing the optimal TURBT. This is the essential first step in managing newly diagnosed and recurrent bladder cancer, ultimately impacting potential multidisciplinary therapies, for both advanced disease and high risk NMIBC. While transurethral resection of the bladder tumor (TURBT) remains the gold standard ‘first step’ in bladder cancer management (both diagnosis and tumor removal), there can be a high rate of residual tumor left behind after TURBT. He details tips to optimize TURBT as well as a checklist of processes for consideration of prognostic factors.
Welcome to the final 2018 issue of Everyday Urology - Oncology Insights. On December 6, 2018, UroToday celebrated its fifteenth year online. Over the years, the site has productively evolved, providing concise and innovative coverage of relevant and clinically important contemporaneous updates in urologic oncology as well as curating cutting edge educational videos and discussions amongst leading experts within the field.
Welcome to Volume 3, Third issue, of Everyday Urology - Oncology Insights. In this issue, the applicability and utility of SpaceOAR® Hydrogel will be reviewed as well as the trials that led to its regulatory approval. SpaceOAR was designed as a means of diminishing rectal radiation toxicity. With a phase III trial reporting a decrease in acute and long-term rectal toxicity, as well as an enhanced patient, reported quality of life outcomes, SpaceOAR is quickly being adopted as a component of prostate cancer radiotherapy. 

Welcome to Volume 3, Issue 2 of Everyday Urology – Oncology Insights. This edition’s cover story by Phillip Koo, MD, Imaging Controversies for Localized and Advanced Prostate Cancer explores the challenging topic of imaging modalities for Prostate Cancer. He discusses the use of multiparametric magnetic resonance imaging (mpMRI) as well as positron emission tomography-computed tomography (PET/CT), C-11 Choline, and 18F-Fluciclovine for both localized and advanced prostate cancer disease management. Dr. Koo also reviews the ability of scoring systems, such as the Prostate Imaging Reporting and Data System (PIRADS) as well as similar tools to enhance stratification assessments and interdisciplinary communication.

Welcome to the first issue of the 2018: Everyday Urology- Oncology Insights. The start of the year has ushered in significant advancements and therapeutic approvals for GU oncology management. Along with these recent developments presented at the 2018 ASCO GU meeting, we anticipate additional and important presentations at upcoming major meetings. 
Welcome to Issue 4 of Everyday Urology - Oncology Insights.  This month, Evan Yu, M.D. and Sumanta (Monty) Kumar Pal, M.D. will review and analyze the impact of current clinical trials on patient care, as described by the cover article, The Importance of Clinical Trials for Genitourinary Malignancies. Drs. Yu and Pal will address numerous and important key clinical questions embracing four main genitourinary malignancies: prostate, bladder/urothelial, renal and testicular germ cell cancers, explaining that if not for the dedication of researchers, investigators, and patients (trial subjects) who collectively dedicate their energies to clinical trials, we would not have the evidence-based information which results in regulatory approval and subsequent US and global access for life-prolonging therapies for the genitourinary cancers we diagnose and manage.
Welcome to Issue 3 of Everyday Urology - Oncology Insights which focuses on the exceptionally rapid and groundbreaking advances in both advanced prostate and bladder cancer evaluation and management. 

Petros Grivas’ cover article, Updates on Immunotherapy for Urothelial Cancer, not only succinctly reviews the five new approved immuno-oncology therapies (IO), aka checkpoint (PD pathway) inhibitors and their milestone clinical trials, but also offers guidance regarding treatment selection strategy as well as IO selection within the context of chemotherapeutic options.  Additionally, he discusses a basis for monitoring efficacy of response, potential biomarkers and genomic markers predictive of patient benefit and also reviews the ongoing possibilities for combination strategies. Clearly, both advanced bladder and kidney cancer care information and subsequent
Optimizing the patient clinical outcome (prolonging survival, preserving quality of life, and preventing complications) while avoiding excessive healthcare economic burden is tantamount to the overall improvement of the healthcare system.  Certainly, combining an integrative, multidisciplinary approach, which can attain these aforementioned goals will align with the “Triple Aim”, which proposes that improving the U.S. health care system requires simultaneous pursuit of three aims: improving the experience of care, improving the health of populations, and reducing per capita costs of health care.  

Our first issue of 2017 emphasizes a well-known, yet an evolving and important, theme: optimizing the successful multidisciplinary collaboration amongst oncologic physicians; and furthermore, the importance of patient involvement, also known as, patient-physician shared decision making (and assuredly, successful integrated care).  This multidimensional approach to decision making and treatment has numerous advantages in all phases of the patient care experience, the physician expectation of successful genitourinary oncology outcomes, and efficiency for the healthcare ecosystem.  The authors of our three featured articles in this issue include the specialties of: urology, cardiology and nuclear medicine.

Over the past year, we’ve been honored to provide you with the inaugural issues of Everyday Urology-Oncology Insights. This fourth issue completes our publications for 2016—a year highlighted by important developments in the optimal management and treatment of patients with genitourinary cancers. Everyday Urology-Oncology Insights has strived in our inaugural year of publication to provide our readership with timely articles, written by internationally renowned GU oncology experts. I’d like to thank our editorial team and our advisory board for their dedication to selecting and reviewing the relevant content of interest for urologists, medical oncologists, radiation oncologists, and radiologists.
In this issue of Everyday Urology-Oncology Insights, we will share with you several articles which are based upon recent presentations from the CME course at the annual Large Urology Group Practice Association (LUGPA) meeting held this past November in Chicago, Illinois. I was honored to be the co-chairman along with my colleague, Dr. David Chaikin. This year’s LUGPA CME program was entitled: “Optimizing Bladder Disease Management”.
Since the inaugural publication of Everyday Urology-Oncology Insights, we have received wonderful feedback and insights from our readers and colleagues, and I am extremely appreciative for all of the suggestions. We will strive to present ongoing educational content which should enhance your specific practice model, and we will always look forward to receiving your feedback for this in order to ensure that this quarterly publication provides you with actionable and useful information.
Welcome to the inaugural issue of Everyday UrologyOncology Insights, brought to you by Digital Science Press, Inc, publishers of UroToday.com. For the past 13 years, UroToday has demonstrated its commitment to providing accurate, timely, evidence-based urology and oncology information to the global community of healthcare providers. With its inception in 2003, there was a recognition that there are a multitude of ongoing scientific publications and medical conferences; nevertheless, an easy to access daily platform to acknowledge, report and accommodates this content did not exist. UroToday.com initiated its web based platform to succinctly aggregate the contemporaneous and most relevant urology content on a real time, daily basis in order to allow busy clinicians to remain up to date with the newest research, approvals, and meeting information.